{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:59:36Z","timestamp":1790873976327,"version":"4.1.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004807","name":"DFG","doi-asserted-by":"publisher","award":["Do491\/10\u20131"],"award-info":[{"award-number":["Do491\/10\u20131"]}],"id":[{"id":"10.13039\/100004807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004807","name":"DFG","doi-asserted-by":"publisher","award":["TRR130"],"award-info":[{"award-number":["TRR130"]}],"id":[{"id":"10.13039\/100004807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>SLE is characterized by two pathogenic key signatures, type I IFN and B-cell abnormalities. How these signatures are interrelated is not known. Type I-II IFN trigger activation of Janus kinase (JAK) \u2013 signal transducer and activator of transcription (STAT). JAK-STAT inhibition is an attractive therapeutic possibility for SLE. We assess STAT1 and STAT3 expression and phosphorylation at baseline and after IFN type I and II stimulation in B-cell subpopulations of SLE patients compared with other autoimmune diseases and healthy controls (HD) and related it to disease activity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Expression of STAT1, pSTAT1, STAT3 and pSTAT3 in B and T cells of 21 HD, 10 rheumatoid arthritis (RA), seven primary Sj\u00f6gren\u2019s (pSS) and 22 SLE patients was analysed by flow cytometry. STAT1 and STAT3 expression and phosphorylation in PBMCs (peripheral blood mononuclear cells) of SLE patients and HD after IFN\u03b1 and IFN\u03b3 incubation were further investigated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>SLE patients showed substantially higher STAT1 but not pSTAT1 in B- and T-cell subsets. Increased STAT1 expression in B-cell subsets correlated significantly with SLEDAI and Siglec-1 on monocytes, a type I IFN marker. STAT1 activation in plasmablasts was IFN\u03b1 dependent while monocytes exhibited dependence on IFN\u03b3.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Enhanced expression of STAT1 by B-cell candidates as a key node of two immunopathogenic signatures (type I IFN and B-cells) related to important immunopathogenic pathways and lupus activity. We show that STAT1 is activated upon IFN\u03b1 exposure in SLE plasmablasts. Thus, Jak inhibitors, targeting JAK-STAT pathways, hold a promise to block STAT1 expression and control plasmablast induction in SLE.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa187","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T19:12:24Z","timestamp":1586373144000},"page":"3435-3442","source":"Crossref","is-referenced-by-count":40,"title":["Elevated STAT1 expression but not phosphorylation in lupus B cells correlates with disease activity and increased plasmablast susceptibility"],"prefix":"10.1093","volume":"59","author":[{"given":"Arman","family":"Aue","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 University Medicine"},{"name":"German Rheumatism Research Center Berlin (DRFZ), Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Szelinski","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 University Medicine"},{"name":"German Rheumatism Research Center Berlin (DRFZ), Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Y","family":"Wei\u00dfenberg","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 University Medicine"},{"name":"German Rheumatism Research Center Berlin (DRFZ), Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Wiedemann","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 University Medicine"},{"name":"German Rheumatism Research Center Berlin (DRFZ), Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Rose","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 University Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia C","family":"Lino","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 University Medicine"},{"name":"German Rheumatism Research Center Berlin (DRFZ), Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"D\u00f6rner","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 University Medicine"},{"name":"German Rheumatism Research Center Berlin (DRFZ), Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,1]]},"reference":[{"key":"2020102707112399000_keaa187-B1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nrrheum.2016.158","article-title":"Beyond pan-B-cell-directed therapy \u2013 new avenues and insights into the pathogenesis of SLE","volume":"12","author":"Dorner","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2020102707112399000_keaa187-B2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/BOR.0000000000000576","article-title":"Postactivated B cells in systemic lupus erythematosus: update on translational aspects and therapeutic considerations","volume":"31","author":"Schrezenmeier","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"2020102707112399000_keaa187-B3","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/imr.12374","article-title":"Cytokine-producing B cells: a translational view on their roles in human and mouse autoimmune diseases","volume":"269","author":"Lino","year":"2016","journal-title":"Immunol Rev"},{"key":"2020102707112399000_keaa187-B4","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020102707112399000_keaa187-B5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1084\/jem.20021553","article-title":"Interferon and granulopoiesis signatures in systemic lupus erythematosus blood","volume":"197","author":"Bennett","year":"2003","journal-title":"J Exp Med"},{"key":"2020102707112399000_keaa187-B6","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/art.23404","article-title":"Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus","volume":"58","author":"Biesen","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2020102707112399000_keaa187-B7","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1136\/annrheumdis-2012-201586","article-title":"IFNalpha and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus","volume":"72","author":"Rose","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2020102707112399000_keaa187-B8","doi-asserted-by":"crossref","first-page":"e000292","DOI":"10.1136\/rmdopen-2016-000292","article-title":"SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjogren\u2019s syndrome","volume":"2","author":"Rose","year":"2016","journal-title":"RMD Open"},{"key":"2020102707112399000_keaa187-B9","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1136\/annrheumdis-2016-210927","article-title":"High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart block","volume":"76","author":"Lisney","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2020102707112399000_keaa187-B10","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1089\/jir.2016.0040","article-title":"Increased levels of STAT1 protein in blood CD4 T cells from systemic lupus erythematosus patients are associated with perturbed homeostasis of activated CD45RA(-)FOXP3(hi) regulatory subset and follow-up disease severity","volume":"37","author":"Goropevsek","year":"2017","journal-title":"J Interferon Cytokine Res"},{"key":"2020102707112399000_keaa187-B11","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s10067-019-04467-8","article-title":"Upregulated expression of STAT3\/IL-17 in patients with systemic lupus erythematosus","volume":"38","author":"Chen","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2020102707112399000_keaa187-B12","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","article-title":"A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE)","volume":"75","author":"Kalunian","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2020102707112399000_keaa187-B13","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2020102707112399000_keaa187-B14","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2020102707112399000_keaa187-B15","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"2020102707112399000_keaa187-B16","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/S0140-6736(19)30546-X","article-title":"Novel paradigms in systemic lupus erythematosus","volume":"393","author":"Dorner","year":"2019","journal-title":"Lancet"},{"key":"2020102707112399000_keaa187-B17","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2020102707112399000_keaa187-B18","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2020102707112399000_keaa187-B19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism Classification Criteria for Primary Sjogren\u2019s Syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2020102707112399000_keaa187-B20","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.3389\/fimmu.2019.02136","article-title":"Identification and characterization of post-activated b cells in systemic autoimmune diseases","volume":"10","author":"Weissenberg","year":"2019","journal-title":"Front Immunol"},{"key":"2020102707112399000_keaa187-B21","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1084\/jem.20130323","article-title":"Naive and memory human B cells have distinct requirements for STAT3 activation to differentiate into antibody-secreting plasma cells","volume":"210","author":"Deenick","year":"2013","journal-title":"J Exp Med"},{"key":"2020102707112399000_keaa187-B22","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.4049\/jimmunol.1502043","article-title":"STAT3 signaling in B cells is critical for germinal center maintenance and contributes to the pathogenesis of murine models of lupus","volume":"196","author":"Ding","year":"2016","journal-title":"J Immunol"},{"key":"2020102707112399000_keaa187-B23","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/art.24449","article-title":"Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells","volume":"60","author":"Karonitsch","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2020102707112399000_keaa187-B24","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/art.10949","article-title":"Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus","volume":"48","author":"Jacobi","year":"2003","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/11\/3435\/34038158\/keaa187.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/11\/3435\/34038158\/keaa187.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T11:59:24Z","timestamp":1603799964000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/59\/11\/3435\/5827798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":24,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,5,1]]},"published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa187","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11]]},"published":{"date-parts":[[2020,5,1]]}}}